Cognitive and Renal Outcomes of Finerenone in Older Adults With Heart Failure With Preserved Ejection Fraction: A Real-World Cohort Study

Heart failure is a condition where the heart struggles to pump blood effectively, but there is a specific type called heart failure with preserved ejection fraction. In this version, the heart muscle squeezes with normal strength, yet it becomes stiff and cannot fill up with enough blood to meet the body's needs. This form of the disease strikes older adults most often, and while it is common, finding treatments that truly change the course of the illness has proven difficult. Alongside the struggle with the heart, many older patients face a silent companion: the gradual loss of memory and thinking skills known as dementia. For years, doctors have wondered if certain heart medications, specifically a class of drugs that block a hormone called aldosterone, might also protect the brain. Some older drugs in this group have shown promise in slowing cognitive decline, leading researchers to ask if a newer, more selective medication could offer the same double benefit for both the heart and the mind.

A team of researchers set out to investigate this question using a massive collection of real-world medical records. They focused on adults aged sixty-five and older who had just been diagnosed with the stiff-heart type of heart failure. The study compared two groups of patients: those who started taking a newer medication called finerenone and those who did not take this drug or any similar heart medication during the same period. The researchers followed these patients for six months to see what happened. Their primary goal was to determine if the group taking finerenone developed dementia or experienced noticeable cognitive decline less often than the group that did not take the drug. As a secondary goal, they also tracked kidney health, looking for signs of acute injury, worsening kidney disease, or the need for dialysis, since the kidneys and heart are closely linked and often suffer together in older adults.

The researchers analyzed data from over half a million patients initially, narrowing the field down to a carefully matched pair of groups to ensure a fair comparison. After balancing factors like age, race, other health conditions, and blood test results, they ended up with two groups of 1,660 patients each. When the six-month period ended, the results regarding the brain were clear. The rate of new dementia or cognitive decline was nearly identical in both groups. About one percent of the patients taking finerenone developed these issues, compared to 1.4 percent of those who did not take the drug. The difference was so small that it could easily be due to chance rather than a real effect of the medication. This finding suggests that, at least in the short term, this newer drug does not provide the same protective shield for the brain that some older heart medications might offer.

However, the story was very different when the researchers looked at the kidneys. The group of patients taking finerenone saw a significant improvement in their kidney outcomes. Only 11.1 percent of those on the drug experienced a major kidney problem, such as acute injury or a rapid decline in function, compared to 20.3 percent of the patients who did not take the medication. This means that for every hundred patients treated with finerenone, roughly nine fewer suffered a serious kidney event compared to those who were not treated. The data indicates that the drug successfully protected the kidneys, a result that aligns with what was already known about its ability to reduce inflammation and scarring in kidney tissue.

The researchers explained that the lack of a brain benefit might be due to how the drug is built. Finerenone has a different chemical structure than the older heart medications that showed cognitive promise. This new structure makes it harder for the drug to cross the barrier that separates the blood from the brain. If the protection of the brain relies on the drug acting directly inside the brain, finerenone might not be able to reach its target effectively. Alternatively, the benefits of these drugs on the brain might take years to appear, and a six-month window might simply be too short to see the change. The study did not prove that the drug harms the brain, nor did it prove that it helps; it simply found no evidence of a benefit in the short term.

In the end, this large look at real-world patients confirms that finerenone is a strong choice for protecting the kidneys in older adults with this specific type of heart failure. It offers a clear safety advantage for the kidneys without causing harm, but it does not appear to offer an immediate shield against memory loss or cognitive decline. The researchers suggest that doctors should continue to prescribe the drug for its heart and kidney benefits, but they should not expect it to prevent dementia in the near future. To know for sure if the drug might help the brain over a longer period, future studies will need to follow patients for several years and use more detailed tests to measure thinking skills. For now, the evidence points to a medicine that keeps the kidneys safe while leaving the question of brain protection open for further investigation.